Loading the records…
Loading the records…
CDC · CDC OFFICE OF ACQUISITION SERVICES
CDC is planning to buy "Pre-Solicitation FY 2025 CDC OS Emerging Public Health Priorities BAA". This is an early notice: it is not taking bids yet. The work is in Atlanta, GA, USA. The original due date (Jan 30, 2025) has passed; check the latest amendment for the current one. In the last 2 years, similar work (matched on the agency only, a loose match) went to 10 or more companies, usually for about $801K per award.
Put together from the facts on this page; the details and sources are below.
Your briefs and their views: My briefs.
Every notice posted under solicitation BAAOSCDC2025 in this department, oldest first.
Standard steps for the notice type; not advice about this buyer.
afety, and security threats, both foreign and domestic. Specifically, CDC works with its partners to monitor health, detect and investigate health problems, conduct research to enhance and implement prevention strategies, develop and promote sound public health policies, promote healthy behaviors, foster safe and healthful environments, respond to current and emerging threats. CDC�s Office of Science (OS) serves as the agency�s authority on scientific quality, integrity, and innovation. The office works agency-wide to advance strategic science�the cornerstone of CDC�s mandate to protect the public�s health. OS staff members collaborate across the agency to provide the scientific expertise, services, and systems that ensure CDC delivers information the world trusts. ACQUISITION OBJECTIVE: PLACE OF PERFORMANCE: All work is intended to take place at the Contractor�s Site. The Government anticipates the following Area(s) of interest will be included in the solicitation: National Center for Emerging Zoonotic and Infectious Diseases (NCEZID): Innovative approaches to pathogen agnostic infectious disease surveillance, culture-independent sequencing, and multi-pathogen bioinformatic and data integration; Wastewater Surveillance Innovation and Applications; Defining Immunologic Correlates of Protection and Safety and Developing Scalable Assays to Measure Dengue Vaccine Efficacy; Novel methodologies to define the environments where people most commonly encounter ticks; Advancing the control of dengue vectors by applying persistent, long-lasting larvicides to household containers that produce Aedes mosquitoes; Elucidating dengue virus shedding in stool and urine for improved interpretation of wastewater surveillance; Research to understand the epidemiology of emerging severe or antifungal-resistant dermatophyte infections in the United States; Innovative methods to identify introduction of Sporothrix brasiliensis to new geographic regions; National Center for Injury Prevention and Control (NCIPC): 9. Planning a longitudinal cohort study to better understand substance use disorder recovery; National Center for Immunization and Respiratory Diseases (NCIRD): 10. Researching the use of insurance claims data to monitor uptake and effectiveness of maternal and pediatric immunizations. CONTEMPLATED ACQUISITION DETAILS: 1. This procurement is anticipated to be solicited as a Broad Agency Announcement (BAA) and will be solicited for full and open competition. 2. The Broad Agency Announcement will be made available via the Government Point of Entry (GPE) SAM.gov (https://sam.gov). 3. The applicable NAICS code is 541715. 4. Firm-Fixed Price or cost reimbursable/CPFF Contracts are anticipated. 5. The anticipated Period of Performance for awarded BAA contracts may vary according to the individual research area and the contractor�s individual technical approach. BAA awards will generally not exceed 36 months and shall not exceed 60 months. 6. The tentative date for Broad Agency Announcement issuance is planned for December 30, 2024. The tentative due date for receipt of Concept Papers is January 30, 2025. 7. Interested contractors must have an active registration, including completion of the annual representations and certifications, in the System for Award Management (SAM) at https://sam.gov to be eligible for award. NOTE: This is not a request for concept papers or proposals. A response to this notice is neither requested nor required. The full BAA solicitation will be posted on www.sam.gov on or around 12/30/2024. Potential offerors shall respond to the solicitation, inclusive of any amendments, in order to be considered for award.
112 award notices on SAM.gov in the last 24 months. Matched by: Same agency (CDC), any industry: a loose match.
Loose match: same agency, any industry. Read the titles before treating these as competitors.
Single-winner award sizes (108): middle half $243K to $7.0M, median $801K; range $14K to $4.5B.
| Winner | Awards | Value | Last |
|---|---|---|---|
| POLOLEI SOLUTIONS, LLC | 5 | $3.3M | Jul 21, 2026 |
| GLAXOSMITHKLINE, LLC | 3 | $1.7B | Mar 27, 2026 |
| RESEARCH TRIANGLE INSTITUTE Durham NC 27709 USA | 3 | $9.8M | Jun 4, 2026 |
| MERCK SHARP & DOHME LLC · $MRK · $67.4B | 2 | $4.5B | Sep 14, 2026 |
| SANOFI VACCINES US INC. | 2 | $1.9B | Nov 19, 2026 |
| Pfizer New York NY 10001 USA | 2 | $1.2B | Jun 3, 2026 |
| SEQIRUS USA INC | 2 | $663.9M | Dec 31, 2024 |
| Moderna Princeton NJ 08540 USA | 2 | $314.2M | Jun 3, 2026 |
| SANOFI PASTEUR INC. | 2 | $233.3M | Dec 31, 2024 |
| ASTRAZENECA PHARMACEUTICALS LP | 2 | $61.0M | Dec 31, 2024 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Notices whose amount is a placeholder such as $999,999,999 are not added in. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
One award's total value against one year of revenue; many awards are paid over several years.
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
No lobbyist on these filings lists a past Centers For Disease Control & Prevention (CDC) job: no revolving-door tie found in these filings. (These are lobbyists the companies pay, not their own staff.)
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
No bills named on these filings under CDC-related issues.
A bill's title is shown only when the filing's own text names it; filings often cite last Congress's bill numbers.
No rules or proposed rules from the department in the last 12 months.
No executive order in the last 12 months names CDC in its title or summary.
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.